BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease. Circulation 2018;138:2216-26. [PMID: 29945934 DOI: 10.1161/CIRCULATIONAHA.118.034456] [Cited by in Crossref: 114] [Cited by in F6Publishing: 19] [Article Influence: 57.0] [Reference Citation Analysis]
Number Citing Articles
1 Stanetic BM, Ostojic M, Kovacevic-Preradovic T, Kos L, Stanetić K, Nikolic A, Bojic M, Huber K. ApPropRiateness of myOcardial revascUlarization assessed by SYNTAX Scores in patients with type 2 diabetes melliTus: the PROUST study. Postepy Kardiol Interwencyjnej 2020;16:153-61. [PMID: 32636899 DOI: 10.5114/aic.2020.96058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Nazarkina ZK, Chelobanov BP, Chernonosova VS, Romanova IV, Karpenko AA, Laktionov PP. Sirolimus-Eluting Electrospun-Produced Matrices as Coatings for Vascular Stents: Dependence of Drug Release on Matrix Structure and Composition of the External Environment. Materials (Basel) 2020;13:E2692. [PMID: 32545664 DOI: 10.3390/ma13122692] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Madhavan MV, Howard JP, Naqvi A, Ben-Yehuda O, Redfors B, Prasad M, Shahim B, Leon MB, Bangalore S, Stone GW, Ahmad Y. Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. Eur Heart J 2021;42:2643-54. [PMID: 34002202 DOI: 10.1093/eurheartj/ehab280] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Marlevi D, Edelman ER. Vascular Lesion-Specific Drug Delivery Systems: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:2413-31. [PMID: 33985687 DOI: 10.1016/j.jacc.2021.03.307] [Cited by in Crossref: 1] [Reference Citation Analysis]
5 Vlieger S, Danzi GB, Kauer F, Oemrawsingh RM, Stojkovic S, IJsselmuiden AJJ, Routledge H, Laanmets P, Roffi M, Fröbert O, Baello P, Wlodarczak A, Puentes A, Polad J, Hildick-Smith D. One-year performance of thin-strut cobalt chromium sirolimus-eluting stent versus thicker strut stainless steel biolimus-eluting coronary stent: a propensity-matched analysis of two international all-comers registries. Coron Artery Dis 2021;32:391-6. [PMID: 33060529 DOI: 10.1097/MCA.0000000000000958] [Reference Citation Analysis]
6 Iglesias JF, Heg D, Roffi M, Tüller D, Lanz J, Rigamonti F, Muller O, Moarof I, Cook S, Weilenmann D, Kaiser C, Cuculi F, Valgimigli M, Jüni P, Windecker S, Pilgrim T. Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. J Am Heart Assoc 2019;8:e013607. [PMID: 31696762 DOI: 10.1161/JAHA.119.013607] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
7 Buiten RA, Ploumen EH, Zocca P, Doggen CJM, van der Heijden LC, Kok MM, Danse PW, Schotborgh CE, Scholte M, de Man FHAF, Linssen GCM, von Birgelen C. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial. JAMA Cardiol 2019;4:659-69. [PMID: 31111862 DOI: 10.1001/jamacardio.2019.1776] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 29.0] [Reference Citation Analysis]
8 Sinha SK, Aggarwal P, Pandey U, Razi M, Kumar A, Krishna V. Ultrathin (60 μm), ultralong (≥40 mm) sirolimus-eluting stent: study of clinical and safety profiles among real-world patients. Anatol J Cardiol 2021;25:111-9. [PMID: 33583818 DOI: 10.14744/AnatolJCardiol.2020.40909] [Reference Citation Analysis]
9 Ajmera P, Pothineni R, Chawla KK, Mantravadi SS, Jariwala PV, Vijan V, Vijan V. Real-World Use Of Ultrathin-Strut Biodegradable Polymer-Coated Sirolimus-Eluting Stents In Patients With Coronary Artery Disease: 6-Month Clinical Outcomes. Vasc Health Risk Manag 2019;15:439-47. [PMID: 31695399 DOI: 10.2147/VHRM.S200699] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Panaich SS, Girotra S. Recurrent Stent Thrombosis: An Interventionalist's Nightmare. J Am Heart Assoc 2021;10:e020728. [PMID: 33870700 DOI: 10.1161/JAHA.121.020728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Monjur MR, Said CF, Bamford P, Parkinson M, Szirt R, Ford T. Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents: a meta-analysis. Open Heart 2020;7:e001394. [PMID: 33046595 DOI: 10.1136/openhrt-2020-001394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Youn YJ, Yoo SY, Lee JW, Ahn SG, Lee SH, Yoon J, Park JH, Choi WG, Cho S, Lim SW, Jang YS, Kwon KH, Lee NH, Doh JH, Kang WC, Jeon DW, Lee BK, Heo JH, Hong BK, Choi HH. Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice. Korean Circ J 2020;50:317-27. [PMID: 31960640 DOI: 10.4070/kcj.2019.0258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kim SH, Kang SH, Lee JM, Chung WY, Park JJ, Yoon CH, Suh JW, Cho YS, Doh JH, Cho JM, Bae JW, Youn TJ, Chae IH. Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial. Catheter Cardiovasc Interv 2020;96:1399-406. [PMID: 31859438 DOI: 10.1002/ccd.28654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
14 Forrestal B, Case BC, Yerasi C, Musallam A, Chezar-Azerrad C, Waksman R. Bioresorbable Scaffolds: Current Technology and Future Perspectives. Rambam Maimonides Med J. 2020;11. [PMID: 32374257 DOI: 10.5041/rmmj.10402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
15 Abhyankar A, Sandhu MS, Polavarapu RS. Twelve-month comparative analysis of clinical outcomes using biodegradable polymer-coated everolimus-eluting stents versus durable polymer-coated everolimus-eluting stents in all-comer patients. Indian Heart J. 2019;71:149-154. [PMID: 31280828 DOI: 10.1016/j.ihj.2019.04.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Bularga A, Meah MN, Doudesis D, Shah ASV, Mills NL, Newby DE, Lee KK. Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. Open Heart 2021;8:e001707. [PMID: 34341097 DOI: 10.1136/openhrt-2021-001707] [Reference Citation Analysis]
17 Gori T. Vascular Wall Reactions to Coronary Stents-Clinical Implications for Stent Failure. Life (Basel) 2021;11:63. [PMID: 33477361 DOI: 10.3390/life11010063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
18 Dudek D, Dziewierz A, Stone G, Wijns W. The year in cardiology 2018: coronary interventions. Eur Heart J 2019;40:195-203. [PMID: 30601991 DOI: 10.1093/eurheartj/ehy882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Berry C. Meta-analyses of moving targets. Eur Heart J 2021;42:2655-6. [PMID: 34115845 DOI: 10.1093/eurheartj/ehab359] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]